S&P Futures
4,047.00 -8.75 (-0.22%) Dow Futures
32,519.00 -81.00 (-0.25%) Nasdaq Futures
12,249.00 -30.25 (-0.25%) Russell 2000 Futures
1,833.20 -3.10 (-0.17%) Crude Oil
113.90 -0.19 (-0.17%) Gold
1,848.00 +0.40 (+0.02%)
Co-Diagnostics, Inc. (CODX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 4.6300 |
| Open | 4.6500 |
| Bid | 5.0200 x 1400 |
| Ask | 5.0000 x 1100 |
| Day's Range | 4.6500 - 5.1800 |
| 52 Week Range | 3.6600 - 11.8200 |
| Volume | |
| Avg. Volume | 342,551 |
| Market Cap | 168.919M |
| Beta (5Y Monthly) | -1.14 |
| PE Ratio (TTM) | 3.79 |
| EPS (TTM) | 1.3120 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.33 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CODX
Related Research
- Co-Diagnostics, Inc.Weekly Stock ListESG StocksRatingFair ValueEconomic Moat4 days agoArgus Research
- Motley Fool
Why Co-Diagnostics Trounced the Market on Thursday
Investors took the measure of healthcare testing products specialist Co-Diagnostics (NASDAQ: CODX) and gave it an enthusiastic thumbs-up on Thursday: The company's stock closed the session more than 7% higher. The stock's upward move was propelled by fresh news from the company about its potential role in combating the latest potential global health threat. Thursday morning, Co-Diagnostics announced that it has leveraged its molecular diagnostics platform to finish the principal design work on a PCR test for monkeypox, a rare and occasionally deadly virus first detected in Southern Africa.
- PR Newswire
Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it has completed the principal design work of a PCR test for the monkeypox virus currently exhibiting a multi-country outbreak.
- PR Newswire
Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 2022 Global Investment Conference, being held in-person and virtually on May 23-26 in Miami, Florida.
